• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMonsanto

Monsanto Has to Pay $289 Million in Damages in First Roundup Cancer Trial

By
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Bloomberg
Bloomberg
Down Arrow Button Icon
August 11, 2018, 9:51 AM ET
US-ENVIRONMENT-HEALTH-TRIAL
Dewayne Johnson reacts after the verdict was read in the case against Monsanto at the Superior Court Of California in San Francisco, California on August 10, 2018. - A California jury on Friday, August 10, 2018 ordered agrochemical giant Monsanto to pay nearly $290 million for failing to warn a dying groundskeeper that its weed killer Roundup might cause cancer. Jurors found Monsanto acted with "malice" and that its weed killers Roundup and the professional grade version RangerPro contributed "substantially" to Dewayne Johnson's terminal illness. (Photo by JOSH EDELSON / POOL / AFP) (Photo credit should read JOSH EDELSON/AFP/Getty Images)Josh Edelson—AFP/Getty Images

Monsanto Co. was socked with $289 million in damages in the first trial over claims that its Roundup weed killer causes cancer.

Dewayne Johnson, a former school groundskeeper whose doctors didn’t think he’d live long enough learn the verdict, prevailed Friday in San Francisco state court after jurors deliberated for three days. The trial was an important test of the evidence against Monsanto and will serve as a template for litigating thousands of other claims over the herbicide.

Johnson was seeking $412 million in damages. Jurors awarded him $39 million for his losses and $250 million to punish the company after finding it liable for a design defect and failing to warn of Roundup’s risks. Monsanto said it will appeal.

“Today’s decision does not change the fact that more than 800 scientific studies and reviews — and conclusions by the U.S. Environmental Protection Agency, the U.S. National Institutes of Health and regulatory authorities around the world — support the fact that glyphosate does not cause cancer, and did not cause Mr. Johnson’s cancer,” Monsanto Vice President Scott Partridge said in a statement.

Germany’s Bayer AG closed a deal to buy Monsanto for $66 billion in June. If the litigation generates large verdicts against Monsanto, it could have a material impact on Bayer’s bottom line, said Chris Perrella, an analyst for Bloomberg Intelligence. Since Roundup is ubiquitous in modern farming, there’s a “huge potential liability,” though it’s very uncertain it will materialize, he said. Bayer investors might not be aware of the risks because many analysts covering the company focus on pharmaceuticals, Perrella said.

Glyphosate, the main ingredient in Roundup, was first approved for use in Monsanto’s weed killer in 1974. While becoming the world’s most popular and widely used herbicide, the question of whether it causes cancer has been hotly debated by environmentalists, regulators, researchers and lawyers — even as Monsanto has insisted for decades that it’s perfectly safe.

Working for a school district in Benicia, California, about 40 miles east of San Francisco, Johnson mixed and sprayed hundreds of gallons of Roundup. He was diagnosed with cancer in 2014, and in July 2017, after chemotherapy and other treatments, his oncologist gave him six months to live.

Johnson’s lawyers, relying on his testimony and expert witnesses, argued that his exposure, including accidents that got him soaked from head to toe in Roundup, caused his non-Hodgkin’s lymphoma.

Monsanto scientists knew of the cancer risk posed by Roundup as far back as the 1970s, but failed to inform the public and instead engaged in a “deliberate effort to distort the truth” as the weed killer generated hefty returns, Johnson’s lawyer, Brent Wisner, told the jury in closing arguments Tuesday.

“Despite the Environmental Protection Agency’s failure to require labeling, we are proud that an independent jury followed the evidence and used its voice to send a message to Monsanto that its years of deception regarding Roundup is over and that they should put consumer safety first over profits,” Wisner said in a statement after the verdict.

Monsanto argued that the type of cancer contracted by Johnson takes many years to form. The short period between Johnson’s first exposure in 2012 and his diagnosis in 2014 made any connection between his contact and the disease impossible, according to the company.

Monsanto lawyer George Lombardi insisted that science has found no connection between Roundup and non-Hodgkin lymphoma. In fact, Lombardi told the jury, no one has yet figured out what causes the disease.

“We don’t know why people get mycosis fungoides,” he said, using the name of the specific form of cancer Johnson has. “It would be nice if we could tell people why they get it, but we can’t.”

The case is Dewayne Johnson v. Monsanto Co., CGC-16-550128, California Superior Court, County of San Francisco (San Francisco).

About the Author
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
Future of Work
Ford CEO has 5,000 open mechanic jobs with up to 6-figure salaries from the shortage of manually skilled workers: 'We are in trouble in our country'
By Marco Quiroz-GutierrezJanuary 31, 2026
1 day ago
placeholder alt text
Economy
'I just don't have a good feeling about this': Top economist Claudia Sahm says the economy quietly shifted and everyone's now looking at the wrong alarm
By Eleanor PringleJanuary 31, 2026
2 days ago
placeholder alt text
Success
Ryan Serhant starts work at 4:30 a.m.—he says most people don’t achieve their dreams because ‘what they really want is just to be lazy’
By Preston ForeJanuary 31, 2026
1 day ago
placeholder alt text
Success
Alexis Ohanian walked out of the LSAT 20 minutes in, went to a Waffle House, and decided he was 'gonna invent a career.' He founded Reddit
By Preston ForeJanuary 31, 2026
1 day ago
placeholder alt text
Big Tech
The Chan Zuckerberg Initiative cut 70 jobs as the Meta CEO’s philanthropy goes all in on mission to 'cure or prevent all disease'
By Sydney LakeFebruary 1, 2026
11 hours ago
placeholder alt text
Economy
Meet the first CEO of the IRS: A Jamie Dimon protege facing a $5 trillion test this tax season
By Shawn TullyJanuary 31, 2026
1 day ago

Latest in Health

Several pictures of people receiving medical treatments including a facelift and oxygen therapy.
HealthSuper Bowl
Hims and Hers Super Bowl ad highlights ‘uncomfortable truth’ about elite healthcare for the rich and ‘broken’ system for the rest
By Jacqueline MunisFebruary 1, 2026
13 hours ago
Healthsleep
9 Best Mattresses for Couples in 2026: Tested and Reviewed
By Christina SnyderJanuary 30, 2026
2 days ago
Healthoutdoor and sporting goods
5 Best Sauna Blankets of 2026: Tested by Recovery Experts
By Christina SnyderJanuary 30, 2026
2 days ago
A person laying on a bed in a store.
Healthmattresses
How to Choose a Mattress: The Ultimate Guide
By Jessica RendallJanuary 30, 2026
2 days ago
HealthScience
As billionaires chase immortality, this startup cofounded by a Harvard genetics professor gets FDA approval for the first partial de-aging human trial
By Marco Quiroz-GutierrezJanuary 30, 2026
3 days ago
C-SuiteFortune 500: Titans and Disruptors of Industry
Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19
By Eva RoytburgJanuary 29, 2026
3 days ago